Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2024
Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Jonathan M Loree, Emma Titmuss, James T Topham, et al.
Current Oncology (Toronto, Ont.)
|
January 20, 2021
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
D Gwyn Bebb, Shantanu Banerji, Normand Blais, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2023
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
Mélina Boutin, James T Topham, Harriet Feilotter, et al.
JTO Clinical and Research Reports
|
September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
Sally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Current Oncology (Toronto, Ont.)
|
May 15, 2023
Consensus Recommendations to Optimize the Detection and Reporting of <i>NTRK</i> Gene Fusions by RNA-Based Next-Generation Sequencing
Tracy L Stockley, Bryan Lo, Adrian Box, et al.
Journal of Medical Genetics
|
December 23, 2022
Development of a comprehensive approach to adult hereditary cancer testing in Ontario
Kathleen Anne Bell, Raymond Kim, Melyssa Aronson, et al.
Oncotarget
|
March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Clinical Colorectal Cancer
|
April 15, 2018
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial
Derek J Jonker, Patricia A Tang, Hagen Kennecke, et al.
European Heart Journal
|
September 24, 2021
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death
Roddy Walsh, Arnon Adler, Ahmad S Amin, et al.
Circulation
|
January 28, 2020
An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome
Arnon Adler, Valeria Novelli, Ahmad S Amin, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2024
Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Jonathan M Loree, Emma Titmuss, James T Topham, et al.
Current Oncology (Toronto, Ont.)
|
January 20, 2021
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
D Gwyn Bebb, Shantanu Banerji, Normand Blais, et al.
Therapeutic Advances in Medical Oncology
|
June 30, 2023
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
Mélina Boutin, James T Topham, Harriet Feilotter, et al.
JTO Clinical and Research Reports
|
September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
Sally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Current Oncology (Toronto, Ont.)
|
May 15, 2023
Consensus Recommendations to Optimize the Detection and Reporting of <i>NTRK</i> Gene Fusions by RNA-Based Next-Generation Sequencing
Tracy L Stockley, Bryan Lo, Adrian Box, et al.
Journal of Medical Genetics
|
December 23, 2022
Development of a comprehensive approach to adult hereditary cancer testing in Ontario
Kathleen Anne Bell, Raymond Kim, Melyssa Aronson, et al.
Oncotarget
|
March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Clinical Colorectal Cancer
|
April 15, 2018
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial
Derek J Jonker, Patricia A Tang, Hagen Kennecke, et al.
European Heart Journal
|
September 24, 2021
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death
Roddy Walsh, Arnon Adler, Ahmad S Amin, et al.
Circulation
|
January 28, 2020
An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome
Arnon Adler, Valeria Novelli, Ahmad S Amin, et al.
Page
of 5